DrugPatentWatch Database Preview
ERLEADA Drug Profile
When do Erleada patents expire, and when can generic versions of Erleada launch?
Erleada is a drug marketed by Janssen Biotech and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in ERLEADA is apalutamide. One supplier is listed for this compound. Additional details are available on the apalutamide profile page.
Summary for ERLEADA
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 49 |
| Patent Applications: | 52 |
| Drug Prices: | Drug price information for ERLEADA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ERLEADA |
| DailyMed Link: | ERLEADA at DailyMed |
Generic Entry Opportunity Date for ERLEADA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for ERLEADA
| 1361232-32-7 |
| 4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide |
| 4-(7-(6-CYANO-5-(TRIFLUOROMETHYL)PYRIDIN-3-YL)-8-OXO-6-THIOXO-5,7-DIAZASPIRO[3.4]OCTAN-5-YL)-2-FLUORO-N-METHYLBENZAMIDE |
| 4-(7-(6-cyano-5-(trifluoroMethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspirooctan-5-yl)-2-fluoro-N-MethylbenzaMide |
| 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide |
| 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide |
| 4T36H88UA7 |
| 956104-40-8 |
| AB0008189 |
| ABP001022 |
| AC-27403 |
| ACN-031562 |
| AK174739 |
| AKOS025401932 |
| AMX10207 |
| apalutamide |
| Apalutamide pound ARN509 pound(c) |
| AR509 |
| ARN 509 |
| ARN-509 |
| Arn-509 (AR inhibitor) |
| ARN509 |
| BC600521 |
| BDBM50094975 |
| Benzamide, 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl- |
| C21H15F4N5O2S |
| CHEMBL3183409 |
| CS-0885 |
| D0S7LG |
| DB11901 |
| DTXSID40241899 |
| EX-A089 |
| GTPL9043 |
| HE419434 |
| HJBWBFZLDZWPHF-UHFFFAOYSA-N |
| HMS3656N12 |
| HY-16060 |
| J-519596 |
| JNJ-56021927 |
| KB-74733 |
| KS-00000SN8 |
| MFCD22380626 |
| MLS006011109 |
| MolPort-027-720-961 |
| NCGC00346725-01 |
| PB27306 |
| QCR-211 |
| RL06020 |
| s2840 |
| SCHEMBL909297 |
| SMR004702891 |
| Tube705 |
| UNII-4T36H88UA7 |
| W-5908 |
| Y0375 |
| ZINC43174901 |
US Patents and Regulatory Information for ERLEADA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for ERLEADA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Singapore | 10201610248S | ➤ Sign Up |
| India | 2387DEN2015 | ➤ Sign Up |
| Spain | 2564388 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
